Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$29 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Obtain Physician Rationale for Continued Antipsychotic Use After Pharmacy Review

Miami, Oklahoma Survey Completed on 12-04-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

Surveyors identified a deficiency related to the facility’s failure to ensure a physician provided a rationale for the continued use of an antipsychotic medication after a consultant pharmacist requested review. One resident had a physician’s order for Zyprexa 5 mg at bedtime for the diagnosis of insomnia, starting on 09/27/24. A pharmaceutical consultant report dated 04/24/25 documented that the resident was receiving Zyprexa 5 mg for insomnia and noted that insomnia was not an approved diagnosis for Zyprexa per CMS guidelines. The pharmacist requested that the physician evaluate the routine use of this psychoactive medication, consider a gradual dose reduction (GDR), and, if a dose reduction was not desired, provide a rationale for its continued use. In the section of the report designated for the physician’s response, there was no order for a dose reduction and no documented rationale for continuing the current dose. Record review showed that the resident’s Zyprexa order remained active on the December 2025 MAR, and the medication continued to be administered, including on 12/01/25 and 12/02/25, with the diagnosis of insomnia unchanged. A medication order audit form showed the Zyprexa 5 mg order had been repeatedly reordered on multiple dates from 10/22/24 through 11/11/25. The facility’s policy on psychotropic medications, revised 12/03/25, required that residents receiving psychotropic medications have GDRs attempted at least twice within the first year in two separate quarters, with documentation of the resident’s response and physician rationale if the dose was returned to a prior level. During interview, the DON stated that pharmacy consultation reports are used to alert the physician to issues such as the need to attempt a GDR, acknowledged that the physician had not addressed the pharmacist’s concerns about Zyprexa, and confirmed that the physician had not followed the facility’s policy regarding GDRs or provided a rationale for continued use.

Long-term care team reviewing survey readiness and plan of correction

We Help Long-Term Care Teams Stay Survey-Ready

We process and analyze inspection reports and plan of correction using AI to extract insights and trends so providers can improve care quality and stay ahead of compliance risks.

Discover our solutions:

An unhandled error has occurred. Reload 🗙